| DuoResp Spiromax (budesonide/formoterol) / Teva |
| Completed | 3 | 605 | Europe, RoW | Budesonide/Formoterol SPIROMAX®, SYMBICORT® TURBOHALER®, SYMBICORT placebo, SPIROMAX Placebo | Teva Branded Pharmaceutical Products R&D, Inc. | Asthma | 03/14 | 03/14 | | |
ELIOT, NCT02062463 / 2013-004630-14: Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Participants With Asthma |
|
|
| Completed | 3 | 485 | Europe | Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX, SPIROMAX®, SYMBICORT TURBOHALER budesonide and formoterol fumarate, SYMBICORT®, TURBOHALER® | Teva Branded Pharmaceutical Products R&D, Inc. | Asthma | 03/15 | 03/15 | | |
2010-019082-29: A double-blind, double-dummy, randomized, placebo- and active-controlled, three-way crossover study to evaluate the effect of Budesonide/Formoterol Spiromax® 80/4.5 mcg Inhalation Powder and Symbicort® Turbohaler® 100/6 mcg on the short-term lower leg growth rate in prepubescent children with persistent asthma. |
|
|
| Completed | 3 | 78 | Europe | Budesonide/Formoterol Spiromax® 80/4.5 mcg Inhalation Powder, BF Spiromax, Symbicort® Turbohaler® 80/4,5 Mikrogramm/Dosis Pulver zur Inhalation, Symbicort® Turbohaler® 80/4,5 Mikrogramm/Dosis Pulver zur Inhalation | Teva Branded Pharmaceutical Products R&D, Inc. | Short term lower leg growth rate in prepubescent children with persistent asthma. | | | | |
2014-001563-12: Efficacy of Symptom-driven treatment with inhaled budesonide/formoterol versus fixed dose fluticasone/salmeterol in COPD Effectiviteit van \'symptoom-gestuurde behandeling met het middel Spiromax® budesonide/formoterol versus een vaste dosering Diskus® fluticasone/salmeterol in COPD. |
|
|
| Ongoing | 3 | 260 | Europe | Seretide, DuoResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder, Seretide, DuoResp Spiromax 160 micrograms / 4.5 micrograms inhalation powder, Seretide | University Medical Center Groningen, TEVA pharma | Chronic obstructive pulmonary disease (COPD) Chronisch obstructieve longziekte (COPD) | | | | |
NCT02495168: Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants |
|
|
| Completed | 3 | 1714 | US | Generic Budesonide/Formoterol Fumarate Dihydrate, Symbicort® (Budesonide/Formoterol Fumarate Dihydrate), Symbicort Turbohaler®, Placebo | Actavis Inc., Teva Pharmaceuticals USA | Asthma | 05/18 | 05/18 | | |
2021-006681-21: Care path consisting of a systematic assessment of asthma patients using digital home monitoring resulting in a patient-centred treatment Zorgpad bestaande uit een systematische beoordeling van astma patiënten met behulp van digitale thuismonitoring wat resulteert in een patiëntgerichte behandeling |
|
|
| Not yet recruiting | 3 | 138 | Europe | Budesonide/formoterol (BF) Digihaler Digital System (DS), Inhalation powder, BF Spiromax | Franciscus Gasthuis & Vlietland, Teva Pharmaceuticals, DSW Transformatiegelden | Asthma Astma, Asthma: alternating airway narrowing and - inflammation Astma: wisselende luchtwegvernauwing en -ontsteking, Diseases [C] - Respiratory Tract Diseases [C08] | | | | |
| Recruiting | 3 | 138 | Europe | Budesonide/Formoterol fumarate dihydrate, Budesonide Formoterol (BF) Digihaler Digital System (DS) | Franciscus Gasthuis, Teva Pharmaceuticals USA | Asthma | 01/25 | 06/25 | | |
